Vir Biotechnology Files 8-K on Security Holder Vote
Ticker: VIR · Form: 8-K · Filed: May 29, 2024 · CIK: 1706431
| Field | Detail |
|---|---|
| Company | Vir Biotechnology, Inc. (VIR) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: VIR
TL;DR
VIR filed an 8-K for a shareholder vote - details TBD.
AI Summary
Vir Biotechnology, Inc. filed an 8-K on May 29, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the nature of the vote or any outcomes.
Why It Matters
This filing indicates a formal process involving shareholder decisions, which could impact corporate governance or strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of Vir Biotechnology's security holders?
The filing does not specify the exact matters submitted for a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 29, 2024.
What is the principal executive office address for Vir Biotechnology?
The address is 1800 Owens Street, Suite 900, San Francisco, California 94158.
What is the IRS Employer Identification Number for Vir Biotechnology?
The IRS Employer Identification Number is 81-2730369.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-29 16:06:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value VIR Nasdaq Global Select
Filing Documents
- d771470d8k.htm (8-K) — 30KB
- 0001193125-24-149139.txt ( ) — 149KB
- vir-20240529.xsd (EX-101.SCH) — 3KB
- vir-20240529_lab.xml (EX-101.LAB) — 18KB
- vir-20240529_pre.xml (EX-101.PRE) — 11KB
- d771470d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIR BIOTECHNOLOGY, INC. Date: May 29, 2024 By: /s/ Marianne De Backer Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer